NCT04530643 - A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 26, 2020

Primary Completion Date

September 7, 2021

Study Completion Date

September 7, 2021

Conditions

Atopic Dermatitis

Interventions

DRUG

HY209 0.3%

25 subjects will be assigned to drug (HY209 0.3% gel).

DRUG

HY209 0.5%

25 subjects will be assigned to drug (HY209 0.5% gel).

DRUG

Placebo

25 subjects will be assigned to drug (Placebo).

Trial Locations (3)

Seoul National University Bundang Hospital, Seongnam-si

Seoul National University Hospital, Seoul

Hallym University Kangnam Scared Heart Hospital, Seoul